KCM
CMMB

Kennedy Capital Management’s Chemomab Therapeutics CMMB Stock Holding History

Kennedy Capital Management’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,006
Closed -$295K – 689
2019
Q3 		$295K Sell
2,006
-1,101
-35% -$214K 0.01% 664
2019
Q2 		$891K Sell
3,107
-18
-0.6% -$6.26K 0.02% 614
2019
Q1 		$1.36M Buy
+3,125
New +$1.58M 0.03% 583

Other funds holding CMMB

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Kennedy Capital Management's CMMB Position: Q4 2019 in Review

Kennedy Capital Management sold out of Chemomab Therapeutics (CMMB) in Q4 2019, closing a stake of 2,006 shares — an estimated $295K sold.

Kennedy Capital Management first reported a position in CMMB in Q1 2019 and held it in 3 quarters. The position peaked at $1.36M in Q1 2019. 5 funds tracked by Wall St. Rank hold CMMB as of Q4 2019.

  • Kennedy Capital Management reported no remaining Chemomab Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Kennedy Capital Management sold 2,006 Chemomab Therapeutics shares in Q4 2019, an estimated $295K.
  • Kennedy Capital Management first reported a position in Chemomab Therapeutics in Q1 2019 and held it in 3 quarters.
  • Kennedy Capital Management's Chemomab Therapeutics position peaked at $1.36M in Q1 2019.
  • 5 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2019.

Based on Kennedy Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.